The Protective Arm Of The Renin Angiotensin System Ras

The Protective Arm of the Renin Angiotensin System: Functional Aspects and Therapeutic Implications is the first comprehensive publication to signal the protective role of a distinct part of the renin–angiotensin system (RAS), providing readers with early insight into a complex system which will become of major medical importance in the near future. Focusing on recent research, The Protective Arm of the Renin Angiotensin System presents a host of new experimental studies on specific components of the RAS, namely angiotensin AT2 receptors (AT2R), the angiotensin (1–7) peptide with its receptor Mas, and the enzyme ACE 2, which exert significant beneficial, health-promoting actions by counterbalancing the well-known harmful arm of the RAS with its classical angiotensin AT1 receptor. This innovative concept of the protective arm of the RAS, examined in this reference, represents an indispensable background and will be a strong support for biomedical students, researchers, cardiologists, surgeons, nephrologists, diabetologists, and endocrinologists, as well as any other physician or researcher concerned with RAS physiology, pathophysiology and clinical implications. Provides a complete understanding of the protective side of the Renin Angiotensin System (RAS) involving angiotensin AT2 receptor, ACE2, and Ang(1-7)/Mas receptor Combines the knowledge of editors who pioneered research on the protective renin angiotensin system including; Dr. Thomas Unger, one of the founders of AT2 receptor research; Dr. Ulrike M. Steckelings, who contributed significantly to first preclinical studies with a novel specific AT2-agonist, and Dr. Robson Santos who pioneered research on angiotensin-(1-7) and its receptor Mas. Shows that the protective RAS axes are able to ameliorate the course of several cardiovascular, renal, metabolic and neurological diseases Provides the basis for the understanding of a novel therapeutic approach to stimulate components of the protective arm of the RAS.

This is the first book addressing in full the most important aspects of the angiotensin-(1-7), the key peptide of the protective axis and the main component in the new modulatory concept of the renin-angiotensin system. It features a detailed review of angiotensin-(1-7) and its receptor Mas, comprising the historical background, enzymatic pathways for generation, functions, integrative aspects of its protective profile, and its therapeutic potential. It also encompasses a comprehensive presentation of current knowledge about its widespread biological actions on several tissues, as well as the most recent scientific achievements, emerging from preclinical and clinical trials. Dr. Santos is a renowned researcher on the Renin-Angiontensin system, with remarkable achievements regarding the role of peptides such as alamandine and angiontensin-(1-7). He has also worked on the potential clinical applicability of angiotensin-(1-7)-related drugs for cardiovascular diseases. He has an extensive publication record in the field, including the publication of the book The Protective Arm of the Renin Angiotensin System (Academic Press, 2015). Angiotensin-(1-7) will make a unique contribution to the literature and will be an important resource for biomedical students and researchers, medical practitioners and any other professional interested in this peptide and its role in the renin-angiotensin system.

The Textbook of Nephro-Endocrinology is the definitive translational reference in the field of nephro-endocrinology, investigating both the endocrine functions of the kidneys and how the kidney acts as a target for hormones from other organ systems. It offers researchers and clinicians expert, gold-standard analyses of nephro-endocrine research and translation into the treatment of diseases such as anemia, chronic kidney disease (CKD), rickets, osteoporosis, and, hypoparathyroidism. Investigates both the endocrine functions of the kidneys and how the kidney acts as a target for hormones from other organ systems Presents a uniquely comprehensive and cross-disciplinary look at all aspects of nephro-endocrine disorders in one reference work Clear translational presentations by the top endocrinologists and nephrologists in each specific hormone or functional/systems field

This book is an open access dissemination of the EU COST Action ADMIRE in Aldosterone/Mineralocorticoid Receptor (MR) physiology and pathophysiology. Aldosterone is the major hormone regulating blood pressure. Alterations in blood levels of aldosterone and genetic mutations in the MR receptor are major causes of hypertension and comorbidities. Many of the drugs in clinical use, and in development for treating hypertension, target aldosterone and MR actions in the kidney and cardiovascular system. The ADMIRE book assembles review chapters from 16 European ADMIRE laboratories providing the latest insights into mechanisms of aldosterone synthesis/secretion, aldosterone/MR physiology and signaling, and the pathophysiological roles of aldosterone/MR activation.

This book on “Renin-Angiotensin System in Cardiovascular Disease” includes 25 chapters, which are organized in three sections, namely (i) modulatory aspects, (ii) pathophysiological aspects, and (iii) pharmacotherapeutic aspects. It includes an updated as well as comprehensive knowledge about molecular and cellular aspects for the role of the renin-angiotensin system (RAS) in the pathophysiology and therapy of cardiovascular diseases such as hypertension, atherosclerosis, ischemic heart disease, and heart failure. This book emphasizes the molecular and cellular mechanisms, signaling transduction pathways involved in the development of different cardiovascular diseases due to the prolonged activation of RAS. Furthermore, biochemical mechanisms are outlined for the inhibition of this system by the blockade of angiotensin converting enzyme as well as angiotensin II type 1 receptors in patients suffering from cardiovascular abnormalities. Since cardiovascular disease is the number one cause of death worldwide, leading to approximately 17.9 million deaths each year, there is a keen interest in understanding the pathogenesis and improving its therapy. In this regard, we can attest that this book provides ample information about essential components of RAS and their role in the development of cardiovascular disease. From the selection of recognized global experts in their area of investigation, this book can be seen to cover diverse cardiovascular aspects and molecular and cellular mechanisms of angiotensin II action for the development of different cardiovascular abnormalities. It is our contention that this book will be most suitable for promoting knowledge in the field of RAS biology and will be of great interest to health professionals involved in both experimental and clinical cardiology as well as academic investigators and cardiovascular scientists, graduate students, and fellows worldwide.

Exploring the contractile activity of smooth muscle segments isolated from various organs of healthy animals and animals with experimentally induced diabetes, she obtained original data about angiotensin II-induced force and time parameters. For the first time, she established the effect of ghrelin on angiotensin II-provoked contraction of the urinary bladder. Original data on the role of both types of angiotensin receptors for the contractile activity of the various segments of the gastrointestinal tract and bladder were obtained. By applying specific software for force and time parameter analysis, the contribution of different types of angiotensin receptors on muscle contractility has been shown. The new methodology was used to analyze the data obtained during the registration of smooth muscle relaxation activity, which allows the determination of not only the magnitude of the mechanical response but also the parameters related to the time and speed of the contractions. Plasma renin activity models have been developed using mathematical approaches to predict the effect of different drug doses on the behavior of the system.

Up-to-date, authoritative and comprehensive, Heart Failure, 4th Edition, provides the clinically relevant information you need to effectively manage and treat patients with this complex cardiovascular problem. This fully revised companion to Braunwald’s Heart Disease helps you make the most of new drug therapies such as angiotensin receptor neprilysin inhibitors (ARNIs), recently improved implantable devices, and innovative patient management strategies. Led by internationally recognized heart failure experts Dr. G. Michael Felker and Dr. Douglas Mann, this outstanding reference gives health care providers the knowledge to improve clinical outcomes in heart failure patients. Focuses on a clinical approach to treating heart failure, resulting from a broad variety of cardiovascular problems. Covers the most recent guidelines and protocols, including significant new updates to ACC, AHA, and HFSA guidelines. Covers key topics such as biomarkers and precision medicine in heart failure and new data on angiotensin receptor neprilysin inhibitors (ARNIs). Contains four new chapters: Natriuretic Peptides in Heart Failure; Amyloidosis as a Cause of Heart Failure; HIV and Heart Failure; and Neuromodulation in Heart Failure. Covers the pathophysiological basis for the development and progression of heart failure. Serves as a definitive resource to prepare for the ABIM’s Heart Failure board exam. 2016 British Medical Association Award: First Prize, Cardiology (3rd Edition).